CADL news

Candel Therapeutics announced the appointment of Martine Zimmermann to its board of directors. Her addition strengthens the company's leadership ahead of expected regulatory filings and commercial growth.

Candel Therapeutics filed an updated corporate presentation to reflect its strategy of tipping the immune system to fight cancer, outlining perspectives for current and future research and development.

Cadrenal Therapeutics entered into a separation agreement with CMO James Ferguson III following his voluntary resignation for July 2026. This leadership change may impact the biotech firm's clinical development strategies.

Candel Therapeutics has entered into an employment agreement with Charles Schoch to serve as Chief Financial Officer effective June 12, 2026, with a base salary of $468,600 and target bonus of 40%. The appointment reflects the company's continued organizational development and financial leadership n…